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Abstract
Background: In increasingly constrained healthcare budgets worldwide, efforts to improve quality and reduce
costs are vital. Quality Improvement Collaboratives (QICs) are often used in healthcare settings to implement
proven clinical interventions within local and national programs. The cost of this method of implementation,
however, is cited as a barrier to use. This systematic review aims to identify and describe studies reporting on costs
and cost-effectiveness of QICs when used to implement clinical guidelines in healthcare.
Methods: Multiple databases (CINAHL, MEDLINE, PsycINFO, EMBASE, EconLit and ProQuest) were searched for
economic evaluations or cost studies of QICs in healthcare. Studies were included if they reported on economic
evaluations or costs of QICs. Two authors independently reviewed citations and full text papers. Key characteristics
of eligible studies were extracted, and their quality assessed against the Consolidated Health Economic Evaluation
Reporting Standards (CHEERS). Evers CHEC-List was used for full economic evaluations. Cost-effectiveness findings
were interpreted through the Johanna Briggs Institute ‘three by three dominance matrix tool’ to guide conclusions.
Currencies were converted to United States dollars for 2018 using OECD and World Bank databases.
Results: Few studies reported on costs or economic evaluations of QICs despite their use in healthcare. Eight
studies across multiple healthcare settings in acute and long-term care, community addiction treatment and
chronic disease management were included. Five were considered good quality and favoured the establishment of
QICs as cost-effective implementation methods. The cost savings to the healthcare setting identified in these
studies outweighed the cost of the collaborative itself.
Conclusions: Potential cost savings to the health care system in both acute and chronic conditions may be
possible by applying QICs at scale. However, variations in effectiveness, costs and elements of the method within
studies, indicated that caution is needed. Consistent identification of costs and description of the elements applied
in QICs would better inform decisions for their use and may reduce perceived barriers. Lack of studies with
negative findings may have been due to publication bias. Future research should include economic evaluations
with societal perspectives of costs and savings and the cost-effectiveness of elements of QICs.
Trial registration: PROSPERO registration number: CRD42018107417.
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Background
A significant challenge facing health care settings is how
to implement proven clinical interventions in practice in
a cost-effective manner [1]. Scarce resources, including
lack of time and staff are often cited as barriers to imple-
mentation [2, 3]. A recent review of medical research
shows health savings from broad research translation,
significantly outweigh the cost of delivering them [3] but
the field of economic evaluation of implementation
strategies is still developing [4]. Decisions to use particu-
lar implementation methods can be better informed by
identifying cost-benefits of methods in addition to health
outcomes [5, 6].
Methods of knowledge translation have been tested
with mixed results. For example, clinical practice guide-
lines aim to translate research into practice and improve
the quality of care and health outcomes for people.
However, studies have shown that the dissemination of
guidelines alone is insufficient to effect change in routine
clinical practice [7]. Education and training of clinicians,
the development of champions of change in organisa-
tions, and audit and feedback mechanisms have been
trialled to improve adherence to guidelines [8]. However,
these strategies lead to only modest effects in quality
improvement [8]. A recent review found that while
multifaceted strategies are more effective, costs associ-
ated with components were difficult to discern and cost-
effectiveness was not explicitly evaluated [9]. Knowledge
translation approaches which are tailored to an organisa-
tion can be successful but may lack transferability to
other settings [10–12]. QICs have been adapted from
manufacturing industry [13] for use across multiple set-
tings by the US Institute for Healthcare Improvement
(IHI) [14]. A QIC is a multifaceted approach to imple-
mentation of evidence-based practices, clinical guidelines
or improved methods for quality and safety. Typically,
they draw participants from multiple healthcare organi-
sations to learn, apply and share improvement methods
over a year or more. Teams are supported by experts
who coach participants to test strategies adapted to their
own setting. By collaborating, participants learn more
effectively, spread improvement ideas and benchmark
their progress against other organisations [14, 15]. Com-
mon components of QICs include face to face training
sessions focussing on healthcare improvement and qual-
ity improvement methods, telephone meetings, feedback
and the use of process improvement methods [13]. QICs
have been used in healthcare systems in several coun-
tries to improve implementation outcomes [15–17].
They are adaptable within complex healthcare systems
and offer a way to scale up implementation across many
different organisations. However, inconsistent results,
multiple elements and perceived cost of establishing,
conducting and sustaining a collaborative are barriers to
their use [17–19]. Wells and colleagues recently identi-
fied 64 QICs reporting effectiveness measures that met
their inclusion criteria [15]. They found that 73% of
these collaboratives reported significant results in diverse
settings such as hospitals, health clinics and nursing
homes. Improvement was associated with targeted clin-
ical practice related to infection control, management of
chronic conditions or prevention of falls, wounds or pain
management [15]. While these improvements were asso-
ciated with cost savings, only four studies reported on
cost-effectiveness outcomes [15]. They identified gaps in
design, reporting and assessment of costs which limited
the information on cost-effectiveness. The costs of estab-
lishing a QIC can be significant, including personnel to
recruit and coordinate activities, development of mate-
rials and education, the time spent by all participants
involved in the collaborative and expenses associated
with face to face meetings [17].
With increasing pressure on the healthcare system to
deliver evidence-based practice with scarce resources,
there is a need to evaluate the cost-effectiveness of
healthcare improvement and knowledge translation
strategies. Economic evaluation can assess implementa-
tion strategies to guide decisions about the choice of
strategy providing value for money.
The aim of this systematic review was to identify and
describe studies that report on the costs and cost-
effectiveness of QICs to inform strategies to implement
clinical guideline recommendations in healthcare.
Methods
The protocol for this systematic review was developed
in advance and was registered with PROSPERO on 7
September 2018; registration number CRD42018107417.
Eligibility criteria
Studies were included in this review if they reported on
initiatives that comprised healthcare clinicians across
teams, professions, or organisations involved in a QIC or
a quality improvement team with the aim of improving
practice over time. Quality improvement teams were in-
cluded if they included the most common components
of QICs as identified by Nadeem et al. [13]. Studies were
included if the collaboratives used multi-modal interven-
tions, such as training, developing implementation plans,
trying out a practice improvement, seeking advice from
experts and people with lived experience and reviewing
plans over time to improve practice [15]. We included
quantitative studies that used full economic evaluation
(i.e. cost-effectiveness, cost-utility analysis, cost-benefit
analysis, cost-consequences analysis); partial economic
evaluations (i.e. cost analyses, cost descriptions, cost
outcome descriptions, cost minimisation studies); and
randomised trials reporting estimates of resource use or
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costs associated with implementation or improvement.
We excluded systematic reviews, study protocols, confer-
ence proceedings, editorials and commentary papers,
effectiveness analyses with no analysis of costs, burden
of disease studies, and cost of illness studies. The
primary outcome of interest was the cost-effectiveness
or cost-benefit of the use of elements of QICs to imple-
ment improvement in healthcare or adherence to clinical
guidelines. A secondary outcome was costs associated
with QICs.
Search strategy and study selection
Five electronic databases were searched on 19 November
2018 (CINAHL, Medline, PsycINFO, EconLit, ProQuest
(Health and Medicine: Social Sciences subsets only)).
Embase was searched on 20 August 2019. Websites of
large organisations interested in healthcare improvement
such as the Institute of Healthcare Improvement (IHI,
USA) and government bodies such as National Health
and Medical Research Council (Australia), National
Health Services and the National Institute for Health
and Care Excellence (UK) and the European Network of
Health Economic Evaluation Databases were searched
for grey literature. Reference lists of included studies
were scanned for potentially eligible studies. Studies
were limited to English language, but no time limits
were imposed on the search strategies. Research librar-
ians with expertise in systematic reviews assisted with
the development of the search strategies. The search
strategy was developed for MEDLINE using medical
subject search headings (MeSH) and text words and
then adapted for use with the other databases. The strat-
egy combined terms relating to quality improvement,
collaborative, guidelines implementation and cost, cost-
benefit or economic analysis. The search strategy for
MEDLINE is attached (Additional file 1). Results are re-
ported per the Preferred Reporting Items of Systematic
Reviews and Meta-Analyses (PRISMA) guidelines [20].
Two authors (LdlP and GR) independently screened ti-
tles and abstracts based on the inclusion criteria detailed
in the review protocol. Full texts of studies identified by
abstract and title screen as having met the inclusion cri-
teria were obtained and reviewed independently (LdlP
and GR). Differences between reviewer’s results were
resolved by discussion and when necessary in consult-
ation with a third review author (MC).
Data extraction
One author (LdlP) extracted data using a modified ver-
sion of the Joanna Briggs Institute (JBI) Data Extraction
form for Economic Evaluations [21]. Another author
(GR) checked the extraction for accuracy. Data was
extracted about the study method, evaluation design,
participants, intervention used, comparator, outcomes,
prices and currency used for costing, time period of ana-
lysis, setting, tools used to measure outcomes and authors
conclusions. This information was presented descriptively
and summarised in Table 1 (Additional file 2). Both costs
of care resulting from improved care and costs of estab-
lishing QICs were identified. Cost components were stan-
dardised by converting currency and year to US dollars for
2018 through the Eurostat-OECD data base and manual
on purchasing power parities for Euros and The World
Bank GDP deflator data base for United States dollar
values [22, 23].
Risk of bias assessment
Two checklists were used to critically appraise the stud-
ies due to the difference in design of studies included.
The 24 item Health Economic Evaluation Reporting
Standards (CHEERS) checklist was used to determine
methodological quality of all the included studies as it
applies to any form of economic evaluation [24]. This is
presented in Table 2a (Additional file 3). The Evers
CHEC-List [25] was also used to assess the full economic
evaluations and is included as Table 2b (Additional file 4)
[26]. A score of one point was assigned to each positive re-
sponse, zero to a negative response or for items that did
not apply. A summary score is calculated at the bottom of
each table with a maximum score of 24 and 19 respect-
ively. This scoring provides an indication of total items
present for each study.
Assessment of generalizability
The currency and year of studies was converted to US
dollars for 2018 using the Eurostat-OECD purchasing
power parities data base for Euros and the World Bank
deflator data base for US dollar updates. This provided
an option to compare results but due to the varied type
of studies and focus on the implementation method
rather than the healthcare intervention, a full transfer-
ability assessment was not conducted.
Data synthesis
Included studies were subjected to data extraction by
the author (LdlP) and information was synthesised to
interpret the findings of full and partial economic evalu-
ations and cost analysis studies. The Johanna Briggs
Institute (JBI) ‘three by three dominance ranking matrix
tool’ was used to interpret findings [27] and was checked
by another author (GR) for consistency. Any inconsist-
encies were resolved by discussion and by consultation
with a third review author (BK). This tool assists in
drawing conclusions about the results of studies in terms
of both cost and effectiveness (health benefits). It classi-
fies results as favoured, unclear or rejected in favour of
the comparator. An intervention was favoured if relative
to its comparator it either (i) was cheaper but more
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effective, (ii) was cheaper but just as effective or (iii) cost
the same but was more effective. An intervention was
rejected if, relative to its comparator, it either (i) was
more expensive and less effective, (ii) was more expen-
sive and just as effective or (iii) cost the same but was
less effective. A judgement would have to be made about
all other scenarios based on other criteria [27]. For in-
stance, an intervention would be favoured if it was more
expensive and more effective than a comparator pro-
vided the associated incremental cost-effectiveness ratio
(ICER) was below the threshold used for assessing cost-
effectiveness e.g. €80,000 per quality adjusted life years
(QALY) in the Netherlands [28].
Results
Study selection
The search identified 8505 citations and after removing
duplicates, 3481 titles and abstracts were reviewed.
Twenty-two full text reviews revealed eight papers that
met the inclusion criteria. PRISMA flowchart at Fig. 1
describes the process of selection [29].
Overview of studies
Table 1 (Additional file 2) presents the overview of char-
acteristics of the studies included in this review. Most
studies describe the costs of establishing a collaborative
to improve quality in healthcare and compared costs to
outcomes. Five of the included studies involved full eco-
nomic analyses using cost-effectiveness analysis (CEA)
or cost utility analysis (CUA) [30–34], whereas three
studies were cost analyses [35–37]. All studies were set
in multi-centre healthcare settings, hospitals, long term
care or community clinics, and related to diverse health
conditions such as Parkinson’s disease, diabetes, obstet-
rics, neonatal intensive care, hip fractures, pressure
ulcers, cardiac care or addiction treatment. All included
clinicians working either nationally or across multiple
states.
Methodological quality
Table 2a (Additional file 3) summarises the methodo-
logical quality of the studies included in this review.
Cost effectiveness study conducted by Broughton
et al. [30], and cost utility studies by Schouten et al.
[33], Makai et al. [32] and Huang et al. [34] were
considered high quality, complying with most of the
items on CHEERS checklist [24]. Item 12 related to
valuation of preferences for outcomes was not ad-
dressed in these studies [24]. A cost analysis by
Bloem et al. [35] and a cost effectiveness study by
Gustafson and colleagues [31] were of moderate qual-
ity. They did not address item 13, related to estimat-
ing costs via a model-based evaluation, items 15 and
16, the choice of model or assumptions or item 20,
Fig. 1 PRISMA flowchart describing the process of study selection
de la Perrelle et al. BMC Health Services Research          (2020) 20:155 Page 4 of 10
how uncertainty was addressed. The cost analysis by
Rogowski et al. [36] was rated low quality on
CHEERS checklist and the cost study by Dranove
et al. [37] study was considered lowest quality as less
than half of all items were addressed. Using the Evers
CHEC-List [25], the full economic evaluations [30–
34] were rated good quality.
Conflicts of interest and uncertainties in data were
addressed by five studies [30, 32–35]. An incremental
cost-effectiveness ratio (ICER) was not applicable for the
cost analyses [35–37] and future costs were not directly
considered for those studies.
Data synthesis
Table 3 (Additional file 5) provides a three by three
dominance ranking matrix (JBI DRM) tool to assist in
interpreting the cost-effectiveness results of the stud-
ies included [27]. In this review, five studies were
classified as favoured interventions (strong domin-
ance) [30, 31, 33, 35, 36], two as unclear [32, 34] and
one rejected [37]. Bloem et al. [35], Broughton et al.
[30] and Schouten et al. [33] all showed reduced costs
and improved health outcomes and are most favoured
interventions. The studies by Gustafson et al. [31]
and Rogowski et al. [36] show reduced costs for
equally effective processes which are next favoured in-
terventions. The study by Makai et al. [32] reported
increased costs and reduced pressure ulcers while
Huang et al. [34] reported that the improvements in
Diabetes care were not cost-effective. These results
are uncertain because while the interventions were
more expensive but also cost effective, most scenarios
analysed yielded ICERs that were above the tradition-
ally accepted thresholds of €80,000/QALY [32] and
US$100,000/QALY [34]. They therefore need to be
assessed against specific priorities for health improve-
ments and expenditure. In a cost analysis, Dranove
et al. [37] were unable to identify cost savings or
health improvements as a result of quality improve-




Five studies [30, 32–35] reported positive clinical out-
comes as a result of using a QIC approach. In studies
involving people with chronic health conditions, quality
improvements led to reduced mortality risk and reduc-
tion in associated health events [33, 35]. For example,
adherence to guidelines for Parkinson’s disease care
achieved via the collaboratives produced improved out-
comes, such as reduction in hip fractures, fewer hospital
admissions, lower mortality risk and fewer disease
related complications [35]. Quality improvement in
diabetes care [33, 34] resulted in reduced scores for dia-
betes risk for cardiovascular disease events and mortal-
ity, reduced lifetime incidence of complications and
improved life expectancy for both men and women. In
both acute and critical care, the improvements led to
reduced associated illness but differed in relation to the
effect on mortality risk [30, 36]. In obstetric care, estab-
lishment of a QIC resulted in reduced post-partum
haemorrhage, reduced mortality and increased numbers
of births in clinics [30]. In neonatal intensive care, a QIC
achieved reductions in infections in critically ill pre-term
babies and reduced surgical interventions but no sig-
nificant difference in mortality was found [36]. Resi-
dents in long term care had reduced incidence of
pressure ulcers and slightly improved quality of life as a
result of a QIC [32].
Gustafson and colleagues tested the effectiveness of
four different elements of a QIC in the context of addic-
tion treatment clinics [31]. This study compared clinic
level coaching, group telephone calls to clinicians, face
to face learning sessions and a combination of these ele-
ments to see which methods were more effective. This
study did not collect patient outcomes but focussed on
three primary process outcomes: waiting time, retention
of patients and annual numbers of new patients. These
process outcomes were chosen, as the link between
treatment programs and patient outcomes was consid-
ered weak [31]. Significant improvements in waiting
time and number of new patients were identified for two
of the interventions: coaching and the combination of all
three elements. A combination of all elements was found
to be more costly than coaching alone although it was
similarly effective [31]. Dranove and colleagues found no
direct links between the clinical outcomes for patients of
hospitals studied and the amount they spent on general
quality improvement activities [37].
Cost-effectiveness and cost savings
Five studies [30, 31, 33, 35, 36] reported favourable cost
findings from the use of QICs. These were related to
savings in the health care system and did not consider
broader costs and benefits such as lost productivity,
non-medical patient costs and carer time. These studies
are considered here in relation to cost effectiveness and
cost savings achieved for the use of QICs across a range
of health conditions and countries. Values provided
below are conversions to US$ for 2018 [22, 23] where
the price year was provided.
Cost-effectiveness
Within the context of diabetes care in the Netherlands
[33], the QIC was found to be cost-effective. For the
large populations of people who live with diabetes there
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are significant medical costs related to medicines and
cardio-vascular disease [33, 34]. The incremental costs
per quality adjusted life year (QALY) of US$1550–1714
compared favourably with other published studies on
diabetes [33]. With a cost of about US$19 per patient for
the QIC over 2 years, the cost-effectiveness was reported
to be significant. In the US, a diabetes care improvement
in public health clinics [34] found lower incidence of
complications but the cost of individual improvements
in care varied and all interventions but the use of an
Angiotensin-converting enzyme (ACE) inhibitor, were
not cost-effective [34].
The cost effectiveness study examining obstetric and
newborn care in Niger [30] found the cost per normal
delivery reduced, with a similar decrease in both num-
bers and costs of deliveries with post-partum haemor-
rhage [30]. The cost of the QIC was calculated to be
US$2.84 per delivery. The incremental cost-effectiveness
was US$335 per disability-adjusted life year (DALY)
averted and the study concluded that if other obstetric
clinics used the collaborative approach, substantive cost
savings could be achieved [30].
In long term care [32], reduction in incidence of non-
severe pressure ulcers using a QIC approach increased
costs of care in the short term. Cost-effectiveness in the
longer term was unclear due to small effects on quality
of life in nursing home populations near the end of life,
and the difficulty in sustaining trained staff to continue
to prevent pressure ulcers. As a preventable condition
however, quality improvement in the prevention and
care of pressure ulcers for a vulnerable population was a
worthy goal [32].
A comparison of four different approaches to imple-
menting QICs (in the context of addiction treatment)
identified cost-effective elements [31]. This study found
that while both coaching and a combination of interven-
tions were equally effective in reducing waiting times
and increasing numbers of new patients there were sig-
nificant differences in costs of the interventions. They
found the estimated cost per clinic for a coaching inter-
vention was US$2878 (no year) compared to US$7930
(no year) for the combination of interventions. They
concluded that the coaching intervention was substan-
tially more cost-effective [31].
Cost analyses
A cost analysis of ParkinsonNet [35] showed annual cost
savings of US$449 per patient by avoiding or delaying
complications or high cost treatments of Parkinson’s
disease. The cost per patient per annum was around
US$30. However, based on a population of 40,000
people with Parkinson’s disease in The Netherlands, they
predicted a national cost saving of over US$17.4 million
per annum as a result of the quality improvement [35].
In the costly area of neonatal intensive care, a cost
analysis study [36] reported significant cost savings per
infant were achieved. While costs varied, the average
savings per hospital in the post intervention year was
US$2.3 million for an average cost of $68,206 per hos-
pital in resources to undertake the QIC [36].
Finally, the study of costs to improve quality of care in
hospitals in United States [37], found a wide variety in
expenditures on quality improvement activities which
were not correlated with condition specific costs. Differ-
ences in costs were not statistically significant. They pre-
sumed that a lack of consensus about the purpose of
quality improvement efforts at the time, led to this vari-
ation in costs and disconnection with outcomes [37].
Costs
Costs of care The costs of clinical treatment were mea-
sured in most studies and included clinic visits or treat-
ment provided in hospital such as ventilation, surgery and
medications, complications or infections [30, 32–36].
Costs were extracted from hospital bills, medical claims
and records maintained by clinicians. Some studies used
estimations of costs to form their data, or surveyed man-
agers to identify costs from budgets [30, 33]; one used
weekly diaries of activities and applied hourly costs for
personnel time [36]. Costs of care were not reported in
two studies [31, 37].
Costs of establishing QICs The most common costs
identified were: program management costs for the QIC
coordinators, time of the participating clinicians in face
to face meetings, education sessions, collecting data,
travel costs, conference calls, data analysis costs, overhead
costs and some capital costs. The cost of developing
evidence-based guidelines was included in the Parkinson-
Net study to give a complete cost of start-up of the network
[35]. Four studies provided a cost per patient of establish-
ment of the QIC. These included US$3.67 per infant deliv-
ery [30], US$30 per person with Parkinson’s disease [35],
US$19 per person with diabetes in Europe [33] and
US$130 per patient with diabetes in USA [34]. Dranove
et al. reported a wide variation in costs of quality improve-
ment activities between hospitals with the highest costs
attributed to meetings [37]. All reported costs are presented
in Table 4 (Additional file 6).
Discussion
There is a need for larger scale and more rapid transla-
tion of evidence-based interventions into practice [34].
However, the cost associated with research translation is
an important consideration for constrained health care
budgets. QICs have been used widely in diverse healthcare
settings and have been effective in improving outcomes
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for patients [38] although the costs of the collaboratives
may be a barrier to their use [35]. This review sought to
identify and describe studies that report on the costs and
cost-effectiveness of QICs in healthcare settings. Although
a recent systematic review of QICs identified 64 studies
on effectiveness, only four reported on cost-effectiveness
[15]. We identified eight studies that reported on costs or
cost-effectiveness of QICs. This included the four studies
identified in the review by Wells et al. so updated that
aspect of the review [15]. Our results confirm that the
consideration of costs of QICs has not been reported in
many studies. This may be because of the difficulty in
defining costs associated with QICs over time and in dif-
ferent contexts [38, 39]. It may be that costs are small in
comparison to operating costs or funded separately to the
health system and of less importance for research [40].
Five of the eight studies in this review showed that QICs
were cost-effective in implementing clinical guidelines [30,
31, 33, 35, 36]. They identified cost savings and improve-
ment in health outcomes for patients in both acute care
and chronic condition management. The costs associated
with the QIC appeared low in relation to savings across
large populations or for reducing the need for high cost
treatments [36, 41]. These studies calculated the cost of
the QIC per patient for the duration of the intervention
which provided useful data compared to overall outcomes
and savings achieved. Where smaller populations are
treated with high cost interventions, the cost per patient
for the QICs would be expected to be higher.
These studies were conducted in different countries or
across states, with different infrastructure costs and
resources. It would be difficult to generalize the costs of
the QICs across such different countries and conditions.
However, they used a similar process to engage clini-
cians and modify practices locally. This indicated that
the QIC methodology was adapted to different condi-
tions with similar set up structures needed. An invest-
ment in QICs was needed and the costs per person
could be best spread across large populations of people
with a condition or where high cost treatments can be
reduced [38].
One study evaluated which element of the QIC inter-
vention was more cost-effective [23]. This demonstrated
that differences that can be achieved in both effective-
ness and cost by the choice of how education or support
was provided to clinicians. Only one study found no
correlation between health outcomes and the costs of
quality improvement activities in hospitals [26].
Although most of the studies captured only medical
costs, most considered that societal effects of health
improvements may increase the cost-effectiveness due
to improved quality of life (QoL). For treatment of
chronic conditions, improved care is likely to result
in long term cost savings, however QoL in long term
care populations was more difficult to measure [32].
Schouten et al. [22] found that a wide range of dis-
ease risk control was achieved in diabetes treatment.
They suggested that outcomes of other chronic condi-
tions may be improved through a QIC approach and
the societal effects may also be higher when consider-
ing better quality of life outcomes. Bloem et al. [23]
similarly identified the potential for improvement of
cost-effectiveness of healthcare for other chronic dis-
orders. They also reported the need to structure
funding sources and medical insurance related to im-
provements in health outcomes.
Rogowski et al. [24] identified the potential for higher
cost savings for expensive health interventions and at
least short-term sustainability of QICs. Widespread
adoption of the interventions may increase costs of
interventions but Rogowski et al. considered that ex-
pected savings and benefits would offset these [24]. The
potential for higher cost savings and effectiveness
through a wider use or broader scale of QICs is a pertin-
ent aspect of these studies for healthcare budgets.
The establishment of collaboratives was shown to re-
quire considerable investment in the initial phases of the
improvements, which then decreased over time of the
collaborative process. QICs were funded in most studies
by national agencies with specialist healthcare improve-
ment staff involved in developing the collaborative,
engaging participants and providing education, guidance
and support for the duration. Only one study identified
the relative cost-effectiveness of different combinations
of elements of a QIC [31]. This suggests an opportunity
to improve cost-effectiveness of QICs by selecting key
elements for uses.
Despite increasing acknowledgement of the import-
ance of patient and public involvement, there was no in-
volvement of members of the public or patients reported
in these studies. Costs were spread across state and
national healthcare systems to scale up improvements
for low per clinic or patient cost. One study included the
external cost of developing guidelines in the assessment
of cost-effectiveness [35] which provided an additional
insight into the costs of developing or adapting inter-
national guidelines to national conditions. In most cases
the clinical guidelines were developed separately to
implementation in healthcare services and funded separ-
ately. Despite this inclusion of the cost of developing
guidelines, the use of the QIC was shown to be cost-
effective [35].
The identified costs of the QIC had similar elements
across the five studies showing cost-effectiveness [30, 31,
33, 35, 36]. Costs were highest for the initial develop-
ment of collaboratives, face to face meetings and travel
for participants, and for multi-factored interventions.
While most studies used similar components of QICs as
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described by Nadeem et al. [13] and IHI [14], only one
study compared the costs of different elements of the
QIC [31]. There is an opportunity to consider which ele-
ments of QICs contribute to cost effectiveness and in
which setting they may be useful. One study included
the cost of development of guidelines and a maintenance
cost for an ongoing collaborative [35]. This provides a
wider consideration of all set up costs for quality im-
provement and the costs to maintain the collaborative
beyond a research study. The local infrastructure costs
varied widely in four studies [31, 34, 36, 37] which made
the cost assessments difficult to compare within and be-
tween studies. Inclusions and exclusions of costs varied
between studies which also made comparisons between
studies difficult. It would be of use to identify common
costs to consider when budgeting for QICs and to allow
for local differences in infrastructure.
The value of these studies shows that savings can be
made to healthcare for quality improvements, the real
set up costs and how to assess benefit. Caution in inter-
preting results is needed as the studies varied in what
was included and costed and the perspective from which
assessment of cost effectiveness was judged. Similarly,
few studies of cost effectiveness of QICs were identified
suggesting that studies with negative results may not
have been published.
A strength of this review is the rigorous and systematic
method used to identify studies and synthesise data. A
comprehensive search strategy was developed and used
in a range of databases. Our search of the grey literature
was an important step given the variety of ways in which
healthcare improvements are reported. The use of both
the CHEERS checklist [24] and Evers CHEC-List [25] to
assess the mixed designs found most studies to be of
good to medium quality. The main limitations of the
review are that only studies published in English were
considered and we did not search trial registers. The few
papers identified may reflect a publication bias or may
indicate economic evaluations of QICs have not been
conducted.
Conclusion
Few cost analyses or cost-effectiveness studies have been
identified to assess the costs and benefits of QICs to
translate research and knowledge into practice. Most
that are included in this review show cost savings or im-
provement in healthcare process and patient outcomes
across acute, long term care and chronic conditions.
Judgement is required in relation to the priority given to
healthcare improvement from a societal perspective
compared to the cost of QICs. The potential to scale up
knowledge translation through QICs and to improve
cost-effectiveness based on these studies is suggested.
The costs of QICs need to be factored into translation of
improvements, and their costs or cost-effectiveness
evaluated to identify savings to healthcare budgets and
benefits to society. A detailed break-down of costs of
QICs may assist in identifying elements of greatest cost
and alternatives that may be effective for cost savings to
the quality improvement process.
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